{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T02:26:57Z","timestamp":1790821617963,"version":"4.1.0"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T00:00:00Z","timestamp":1668556800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"PSP-France Foundation"},{"DOI":"10.13039\/501100007492","name":"Bettencourt-Schueller Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007492","id-type":"DOI","asserted-by":"publisher"}]},{"name":"GPR BRAIN_2030"},{"DOI":"10.13039\/501100004792","name":"Minist\u00e8re de l\u2019Enseignement Sup\u00e9rieur et de la Recherche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004792","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative 2 Joint","doi-asserted-by":"publisher","award":["116060"],"award-info":[{"award-number":["116060"]}],"id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007601","name":"European Union\u2019s Horizon 2020 research and innovation program and EFPIA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Sir Henry Dale Fellowship"},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000288","name":"Royal Society","doi-asserted-by":"publisher","award":["206248\/Z\/17\/Z"],"award-info":[{"award-number":["206248\/Z\/17\/Z"]}],"id":[{"id":"10.13039\/501100000288","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017510","name":"UK Dementia Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100017510","id-type":"DOI","asserted-by":"publisher"}]},{"name":"DRI Ltd"},{"DOI":"10.13039\/501100000265","name":"UK Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017506","name":"Alzheimer\u2019s Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100017506","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002283","name":"Alzheimer\u2019s Research UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002283","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Swiss State Secretariat","award":["17.00038"],"award-info":[{"award-number":["17.00038"]}]},{"name":"Defitech Center for Interventional Neurotherapies\u2014NeuroRestore"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Progressive supranuclear palsy is a primary tauopathy affecting both neurons and glia and is responsible for both motor and cognitive symptoms. Recently, it has been suggested that progressive supranuclear palsy tauopathy may spread in the brain from cell to cell in a \u2018prion-like\u2019 manner. However, direct experimental evidence of this phenomenon, and its consequences on brain functions, is still lacking in primates.<\/jats:p>\n               <jats:p>In this study, we first derived sarkosyl-insoluble tau fractions from post-mortem brains of patients with progressive supranuclear palsy. We also isolated the same fraction from age-matched control brains. Compared to control extracts, the in vitro characterization of progressive supranuclear palsy-tau fractions demonstrated a high seeding activity in P301S-tau expressing cells, displaying after incubation abnormally phosphorylated (AT8- and AT100-positivity), misfolded, filamentous (pentameric formyl thiophene acetic acid positive) and sarkosyl-insoluble tau. We bilaterally injected two male rhesus macaques in the supranigral area with this fraction of progressive supranuclear palsy-tau proteopathic seeds, and two other macaques with the control fraction. The quantitative analysis of kinematic features revealed that progressive supranuclear palsy-tau injected macaques exhibited symptoms suggestive of parkinsonism as early as 6 months after injection, remaining present until euthanasia at 18 months. An object retrieval task showed the progressive appearance of a significant dysexecutive syndrome in progressive supranuclear palsy-tau injected macaques compared to controls. We found AT8-positive staining and 4R-tau inclusions only in progressive supranuclear palsy-tau injected macaques. Characteristic pathological hallmarks of progressive supranuclear palsy, including globose and neurofibrillary tangles, tufted astrocytes and coiled bodies, were found close to the injection sites but also in connected brain regions that are known to be affected in progressive supranuclear palsy (striatum, pallidum, thalamus). Interestingly, while glial AT8-positive lesions were the most frequent near the injection site, we found mainly neuronal inclusions in the remote brain area, consistent with a neuronal transsynaptic spreading of the disease.<\/jats:p>\n               <jats:p>Our results demonstrate that progressive supranuclear palsy patient-derived tau aggregates can induce motor and behavioural impairments in non-human primates related to the prion-like seeding and spreading of typical pathological progressive supranuclear palsy lesions. This pilot study paves the way for supporting progressive supranuclear palsy-tau injected macaque as a relevant animal model to accelerate drug development targeting this rare and fatal neurodegenerative disease.<\/jats:p>","DOI":"10.1093\/brain\/awac428","type":"journal-article","created":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T07:48:35Z","timestamp":1668584915000},"page":"2524-2534","source":"Crossref","is-referenced-by-count":35,"title":["Tau seeds from patients induce progressive supranuclear palsy pathology and symptoms in primates"],"prefix":"10.1093","volume":"146","author":[{"given":"Morgane","family":"Darricau","sequence":"first","affiliation":[{"name":"University of Bordeaux, CNRS, Institut des Maladies Neurod\u00e9g\u00e9n\u00e9ratives, UMR 5293 , F-33000 Bordeaux , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taxiarchis","family":"Katsinelos","sequence":"additional","affiliation":[{"name":"UK Dementia Research Institute, Department of Clinical Neurosciences, University of Cambridge , CB2 0AH Cambridge , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavio","family":"Raschella","sequence":"additional","affiliation":[{"name":"Swiss Federal Institute of Technology (EPFL) , CH-1011 Lausanne , Switzerland"},{"name":"Defitech Center for Interventional Neurotherapies (NeuroRestore) , CH-1011 Lausanne , Switzerland"},{"name":"Centre Hospitalier Universitaire Vaudois (CHUV) , CH-1011 Lausanne , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomislav","family":"Milekovic","sequence":"additional","affiliation":[{"name":"Swiss Federal Institute of Technology (EPFL) , CH-1011 Lausanne , Switzerland"},{"name":"Defitech Center for Interventional Neurotherapies (NeuroRestore) , CH-1011 Lausanne , Switzerland"},{"name":"Centre Hospitalier Universitaire Vaudois (CHUV) , CH-1011 Lausanne , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Crochemore","sequence":"additional","affiliation":[{"name":"University of Bordeaux, CNRS, Institut des Maladies Neurod\u00e9g\u00e9n\u00e9ratives, UMR 5293 , F-33000 Bordeaux , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Li","sequence":"additional","affiliation":[{"name":"Motac Neuroscience , F-33000 Bordeaux , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5744-4142","authenticated-orcid":false,"given":"Gr\u00e9goire","family":"Courtine","sequence":"additional","affiliation":[{"name":"Swiss Federal Institute of Technology (EPFL) , CH-1011 Lausanne , Switzerland"},{"name":"Defitech Center for Interventional Neurotherapies (NeuroRestore) , CH-1011 Lausanne , Switzerland"},{"name":"Centre Hospitalier Universitaire Vaudois (CHUV) , CH-1011 Lausanne , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William A","family":"McEwan","sequence":"additional","affiliation":[{"name":"UK Dementia Research Institute, Department of Clinical Neurosciences, University of Cambridge , CB2 0AH Cambridge , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1723-9045","authenticated-orcid":false,"given":"Benjamin","family":"Dehay","sequence":"additional","affiliation":[{"name":"University of Bordeaux, CNRS, Institut des Maladies Neurod\u00e9g\u00e9n\u00e9ratives, UMR 5293 , F-33000 Bordeaux , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0410-4638","authenticated-orcid":false,"given":"Erwan","family":"Bezard","sequence":"additional","affiliation":[{"name":"University of Bordeaux, CNRS, Institut des Maladies Neurod\u00e9g\u00e9n\u00e9ratives, UMR 5293 , F-33000 Bordeaux , France"},{"name":"Motac Neuroscience , F-33000 Bordeaux , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3713-227X","authenticated-orcid":false,"given":"Vincent","family":"Planche","sequence":"additional","affiliation":[{"name":"University of Bordeaux, CNRS, Institut des Maladies Neurod\u00e9g\u00e9n\u00e9ratives, UMR 5293 , F-33000 Bordeaux , France"},{"name":"CHU de Bordeaux, P\u00f4le de Neurosciences Cliniques, Centre M\u00e9moire de Ressources et de Recherche , F-33000 Bordeaux , France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,11,16]]},"reference":[{"key":"2023061215212455800_awac428-B1","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/mds.26987","article-title":"Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria: MDS clinical diagnostic criteria for PSP","volume":"32","author":"H\u00f6glinger","year":"2017","journal-title":"Mov Disord"},{"key":"2023061215212455800_awac428-B2","doi-asserted-by":"crossref","first-page":"101644","DOI":"10.1016\/j.pneurobio.2019.101644","article-title":"Four-repeat tauopathies","volume":"180","author":"R\u00f6sler","year":"2019","journal-title":"Prog Neurobiol"},{"key":"2023061215212455800_awac428-B3","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s00401-020-02158-2","article-title":"Distribution patterns of tau pathology in progressive supranuclear palsy","volume":"140","author":"Kovacs","year":"2020","journal-title":"Acta Neuropathol (Berl"},{"key":"2023061215212455800_awac428-B4","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1001\/jamaneurol.2018.2505","article-title":"Mechanisms of cell-to-cell transmission of pathological tA review","volume":"76","author":"Gibbons","year":"2019","journal-title":"JAMA Neurol"},{"key":"2023061215212455800_awac428-B5","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1038\/s41467-022-28896-3","article-title":"Tau deposition patterns are associated with functional connectivity in primary tauopathies","volume":"13","author":"Franzmeier","year":"2022","journal-title":"Nat Commun"},{"key":"2023061215212455800_awac428-B6","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/S1474-4422(20)30238-6","article-title":"Potential human transmission of amyloid \u03b2 pathology: Surveillance and risks","volume":"19","author":"Lauwers","year":"2020","journal-title":"Lancet Neurol"},{"key":"2023061215212455800_awac428-B7","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.neuron.2014.04.047","article-title":"Distinct tau prion strains propagate in cells and mice and define different tauopathies","volume":"82","author":"Sanders","year":"2014","journal-title":"Neuron"},{"key":"2023061215212455800_awac428-B8","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1212\/WNL.44.11.2015","article-title":"Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy)","volume":"44","author":"Hauw","year":"1994","journal-title":"Neurology"},{"key":"2023061215212455800_awac428-B9","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1084\/jem.20160833","article-title":"Unique pathological tau conformers from Alzheimer\u2019s brains transmit tau pathology in nontransgenic mice","volume":"213","author":"Guo","year":"2016","journal-title":"J Exp Med"},{"key":"2023061215212455800_awac428-B10","doi-asserted-by":"crossref","first-page":"9648","DOI":"10.1073\/pnas.0403015101","article-title":"Targeting expression of expanded polyglutamine proteins to the endoplasmic reticulum or mitochondria prevents their aggregation","volume":"101","author":"Rousseau","year":"2004","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2023061215212455800_awac428-B11","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1016\/j.celrep.2018.04.056","article-title":"Unconventional secretion mediates the trans-cellular spreading of tau","volume":"23","author":"Katsinelos","year":"2018","journal-title":"Cell Rep"},{"key":"2023061215212455800_awac428-B12","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1073\/pnas.1607215114","article-title":"Cytosolic Fc receptor TRIM21 inhibits seeded tau aggregation","volume":"114","author":"McEwan","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2023061215212455800_awac428-B13","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nmeth.2019","article-title":"Fiji: An open-source platform for biological-image analysis","volume":"9","author":"Schindelin","year":"2012","journal-title":"Nat Methods"},{"key":"2023061215212455800_awac428-B14","author":"Goedert"},{"key":"2023061215212455800_awac428-B15","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/nature20118","article-title":"A brain\u2013spine interface alleviating gait deficits after spinal cord injury in primates","volume":"539","author":"Capogrosso","year":"2016","journal-title":"Nature"},{"key":"2023061215212455800_awac428-B16","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/ana.410430308","article-title":"Effects of the nicotinic acetylcholine receptor agonist SIB-1508Y on object retrieval performance in MPTP-treated monkeys: Comparison with levodopa treatment","volume":"43","author":"Schneider","year":"1998","journal-title":"Ann Neurol"},{"key":"2023061215212455800_awac428-B17","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.neurobiolaging.2021.07.009","article-title":"Lack of limbic-predominant age-related TDP-43 encephalopathy (LATE) neuropathological changes in aged macaques with memory impairment","volume":"107","author":"Darricau","year":"2021","journal-title":"Neurobiol Aging"},{"key":"2023061215212455800_awac428-B18","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1750-3639.2010.00433.x","article-title":"Specific detection of pathological three-repeat tau after pretreatment with potassium permanganate and oxalic acid in PSP\/CBD brains: Selective detection of 3R tau","volume":"21","author":"Uchihara","year":"2011","journal-title":"Brain Pathol"},{"key":"2023061215212455800_awac428-B19","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1093\/brain\/awab374","article-title":"Brain injections of glial cytoplasmic inclusions induce a multiple system atrophy-like pathology","volume":"145","author":"Teil","year":"2022","journal-title":"Brain"},{"key":"2023061215212455800_awac428-B20","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/s41592-019-0470-3","article-title":"Moving beyond P values: Data analysis with estimation graphics","volume":"16","author":"Ho","year":"2019","journal-title":"Nat Methods"},{"key":"2023061215212455800_awac428-B21","doi-asserted-by":"crossref","first-page":"11860","DOI":"10.1523\/JNEUROSCI.3644-07.2007","article-title":"Converging evidence for a fronto-basal-ganglia network for inhibitory control of action and cognition","volume":"27","author":"Aron","year":"2007","journal-title":"J Neurosci"},{"key":"2023061215212455800_awac428-B22","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1007\/s00415-018-9134-y","article-title":"The applause sign in frontotemporal lobar degeneration and related conditions","volume":"266","author":"Sch\u00f6necker","year":"2019","journal-title":"J Neurol"},{"key":"2023061215212455800_awac428-B23","doi-asserted-by":"crossref","first-page":"9535","DOI":"10.1073\/pnas.1301175110","article-title":"Brain homogenates from human tauopathies induce tau inclusions in mouse brain","volume":"110","author":"Clavaguera","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2023061215212455800_awac428-B24","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s40478-019-0771-x","article-title":"Encephalopathy induced by Alzheimer brain inoculation in a non-human primate","volume":"7","author":"Gary","year":"2019","journal-title":"Acta Neuropathol Commun"},{"key":"2023061215212455800_awac428-B25","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s40478-021-01141-6","article-title":"Tau assemblies do not behave like independently acting prion-like particles in mouse neural tissue","volume":"9","author":"Miller","year":"2021","journal-title":"Acta Neuropathol Commun"},{"key":"2023061215212455800_awac428-B26","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s13024-021-00476-x","article-title":"Cellular and pathological heterogeneity of primary tauopathies","volume":"16","author":"Chung","year":"2021","journal-title":"Mol Neurodegener"},{"key":"2023061215212455800_awac428-B27","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41586-021-03911-7","article-title":"Structure-based classification of tauopathies","volume":"598","author":"Shi","year":"2021","journal-title":"Nature"},{"key":"2023061215212455800_awac428-B28","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/s41582-021-00541-5","article-title":"Evolving concepts in progressive supranuclear palsy and other 4-repeat tauopathies","volume":"17","author":"Stamelou","year":"2021","journal-title":"Nat Rev Neurol"},{"key":"2023061215212455800_awac428-B29","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/NEN.0000000000000030","article-title":"Glial and neuronal tau pathology in tauopathies: Characterization of disease-specific phenotypes and tau pathology progression","volume":"73","author":"Ferrer","year":"2014","journal-title":"J Neuropathol Exp Neurol"},{"key":"2023061215212455800_awac428-B30","doi-asserted-by":"crossref","first-page":"6853","DOI":"10.1523\/JNEUROSCI.21-17-06853.2001","article-title":"Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson\u2019s disease","volume":"21","author":"Bezard","year":"2001","journal-title":"J Neurosci"},{"key":"2023061215212455800_awac428-B31","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1385\/MN:28:3:209","article-title":"Time-course of nigrostriatal degeneration in a progressive MPTP-lesioned macaque model of Parkinson\u2019s disease","volume":"28","author":"Meissner","year":"2003","journal-title":"Mol Neurobiol"},{"key":"2023061215212455800_awac428-B32","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1111\/j.1460-9568.2006.05077.x","article-title":"Effects of nicotinic therapies on attention and executive functions in chronic low-dose MPTP-treated monkeys","volume":"24","author":"Decamp","year":"2006","journal-title":"Eur J Neurosci"},{"issue":"Pt A","key":"2023061215212455800_awac428-B33","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.neuropharm.2016.07.012","article-title":"An evaluation of istradefylline treatment on parkinsonian motor and cognitive deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque models","volume":"110","author":"Ko","year":"2016","journal-title":"Neuropharmacology"},{"key":"2023061215212455800_awac428-B34","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aaz9165","article-title":"Identification of distinct pathological signatures induced by patient-derived \u03b1-synuclein structures in nonhuman primates","volume":"6","author":"Bourdenx","year":"2020","journal-title":"Sci Adv"},{"key":"2023061215212455800_awac428-B35","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/ncb1901","article-title":"Transmission and spreading of tauopathy in transgenic mouse brain","volume":"11","author":"Clavaguera","year":"2009","journal-title":"Nat Cell Biol"},{"key":"2023061215212455800_awac428-B36","doi-asserted-by":"crossref","first-page":"11406","DOI":"10.1523\/JNEUROSCI.1230-17.2017","article-title":"Pathological tau strains from human brains recapitulate the diversity of tauopathies in nontransgenic mouse brain","volume":"37","author":"Narasimhan","year":"2017","journal-title":"J Neurosci Off J Soc Neurosci"},{"key":"2023061215212455800_awac428-B37","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s40478-021-01266-8","article-title":"Transmission of amyloid-beta and tau pathologies is associated with cognitive impairments in a primate","volume":"9","author":"Lam","year":"2021","journal-title":"Acta Neuropathol Commun"},{"key":"2023061215212455800_awac428-B38","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.gene.2004.07.013","article-title":"Tau gene (MAPT) sequence variation among primates","volume":"341","author":"Holzer","year":"2004","journal-title":"Gene"},{"key":"2023061215212455800_awac428-B39","doi-asserted-by":"crossref","first-page":"6132","DOI":"10.3390\/ijms22116132","article-title":"Tau seeding mouse models with patient brain-derived aggregates","volume":"22","author":"Robert","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2023061215212455800_awac428-B40","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3389\/fnins.2015.00064","article-title":"Lessons from the analysis of nonhuman primates for understanding human aging and neurodegenerative diseases","volume":"9","author":"Verdier","year":"2015","journal-title":"Front Neurosci"},{"key":"2023061215212455800_awac428-B41","author":"Laurens"},{"key":"2023061215212455800_awac428-B42","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1093\/brain\/awm104","article-title":"Pathological tau burden and distribution distinguishes progressive supranuclear palsy-parkinsonism from Richardson\u2019s syndrome","volume":"130","author":"Williams","year":"2007","journal-title":"Brain J Neurol"}],"container-title":["Brain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/brain\/advance-article-pdf\/doi\/10.1093\/brain\/awac428\/48911213\/awac428.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/brain\/article-pdf\/146\/6\/2524\/50572916\/awac428.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/brain\/article-pdf\/146\/6\/2524\/50572916\/awac428.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T17:00:14Z","timestamp":1686589214000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/brain\/article\/146\/6\/2524\/6830655"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,16]]},"references-count":42,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,11,16]]},"published-print":{"date-parts":[[2023,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/brain\/awac428","relation":{},"ISSN":["0006-8950","1460-2156"],"issn-type":[{"value":"0006-8950","type":"print"},{"value":"1460-2156","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,6]]},"published":{"date-parts":[[2022,11,16]]}}}